Online citations, reference lists, and bibliographies.
← Back to Search

Trimodality Therapy For Malignant Pleural Mesothelioma: Results From An EORTC Phase II Multicentre Trial

P. V. Van Schil, P. Baas, R. Gaafar, A. Maat, M. van de Pol, Boskabadi Hasan, H. Klomp, A. M. Abdelrahman, J. Welch, J. Van Meerbeeck
Published 2010 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The European Organisation for Research and Treatment of Cancer (EORTC; protocol 08031) phase II trial investigated the feasibility of trimodality therapy consisting of induction chemotherapy followed by extrapleural pneumonectomy and post-operative radiotherapy in patients with malignant pleural mesothelioma (with a severity of cT3N1M0 or less). Induction chemotherapy consisted of three courses of cisplatin 75 mg·m−2 and pemetrexed 500 mg·m−2. Nonprogressing patients underwent extrapleural pneumonectomy followed by post-operative radiotherapy (54 Gy, 30 fractions). Our primary end-point was “success of treatment” and our secondary end-points were toxicity, and overall and progression-free survival. 59 patients were registered, one of whom was ineligible. Subjects’ median age was 57 yrs. The subjects’ TNM scores were as follows: cT1, T2 and T3, 36, 16 and six patients, respectively; cN0 and N1, 57 and one patient, respectively. 55 (93%) patients received three cycles of chemotherapy with only mild toxicity. 46 (79%) patients received surgery and 42 (74%) had extrapleural pneumonectomy with a 90-day mortality of 6.5%. Post-operative radiotherapy was completed in 37 (65%) patients. Grade 3–4 toxicity persisted after 90 days in three (5.3%) patients. Median overall survival time was 18.4 months (95% CI 15.6–32.9) and median progression-free survival was 13.9 months (95% CI 10.9–17.2). Only 24 (42%) patients met the definition of success (one-sided 90% CI 0.36–1.00). Although feasible, trimodality therapy in patients with mesothelioma was not completed within the strictly defined timelines of this protocol and adjustments are necessary.
This paper references
10.1016/S0360-3016(02)04151-2
Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma.
A. Ahamad (2003)
Common Terminology Criteria for Adverse Events (CTCAE) v3.0による胃癌術後合併症の解析
高橋 聡 (2006)
10.1097/JTO.0B013E318156AF3B
Mesothelioma: benefit from surgical resection is questionable.
T. Treasure (2007)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
10.6004/JNCCN.2012.0006
[Malignant pleural mesothelioma].
Q. Kong (1983)
10.1510/icvts.2008.197160
Does video-assisted thoracoscopic decortication in advanced malignant mesothelioma improve prognosis?
Vivek Srivastava (2009)
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy. A randomized multicenter phase II trial
10.1378/CHEST.108.4.1122
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.
V. Rusch (1995)
10.1016/J.LUNGCAN.2005.03.008
Malignant pleural mesothelioma: staging systems.
P. V. Schil (2005)
10.1016/J.JTCVS.2007.02.014
Ten traps for the unwary in surgical series: a case study in mesothelioma reports.
T. Treasure (2007)
Multicenter trial of neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma
W Weder (2007)
10.1016/J.ATHORACSUR.2007.06.066
Malignant pleural mesothelioma: surgical management in 285 patients.
P. Schipper (2008)
10.1200/JCO.2008.17.5604
Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
M. D. de Perrot (2009)
10.1067/MTC.2001.116560
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
V. Rusch (2001)
10.1016/S0039-6109(02)00033-6
Malignant mesothelioma: options for management.
S. Singhal (2002)
10.1016/j.jtcvs.2007.10.054
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
R. Flores (2008)
10.1016/J.ATHORACSUR.2007.04.076
Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma.
D. Rice (2007)
10.1634/THEONCOLOGIST.12-7-850
Multidisciplinary treatment of malignant pleural mesothelioma.
G. Ceresoli (2007)
10.1016/j.ejcts.2008.06.010
Open lung-sparing surgery for malignant pleural mesothelioma: the benefits of a radical approach within multimodality therapy.
A. Nakas (2008)
10.1002/14651858.CD005574.PUB2
Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma.
J. Green (2007)
10.1016/j.athoracsur.2009.01.026
Prognostic features of long-term survivors after surgical management of malignant pleural mesothelioma.
T. Yan (2009)
10.1016/J.EJSO.2004.08.014
Improved survival with VATS pleurectomy-decortication in advanced malignant mesothelioma.
J. Halstead (2005)
10.1093/ANNONC/MDM093
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2007)
10.1097/JTO.0b013e3181b7d470
The Mars trial: resolution of the surgical controversies in mesothelioma?
V. Rusch (2009)
10.1136/BMJ.328.7434.237
Radical surgery for mesothelioma
T. Treasure (2004)
10.1097/JTO.0b013e31818b174d
Treatment of Malignant Pleural Mesothelioma with Carboplatin, Liposomized Doxorubicin, and Gemcitabine: A Phase II Study
G. Hillerdal (2008)
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy . A randomized multicenter phase II trial ( SAKK 1704 )
A Ahamad
Radical surgery for mesothelioma. The epidemic is still to peak and we need more research to manage it
T Treasure (2004)
10.1200/JCO.20005.14.589
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1097/JTO.0b013e3181ae26ae
The Mesothelioma and Radical Surgery Randomized Controlled Trial: The MARS Feasibility Study
T. Treasure (2009)
10.1093/ANNONC/MDH059
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
10.1200/JCO.2008.20.3943
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
L. Krug (2009)



This paper is referenced by
10.2217/fon.12.14
Systemic treatment of malignant pleural mesothelioma.
F. Grosso (2012)
10.1007/s11864-014-0314-4
Local and Systemic Therapies for Malignant Pleural Mesothelioma
D. Gomez (2014)
Randomized Phase II Trial of Adjuvant WT-1 Analog Peptide Vaccine in Patients with Malignant Pleural Mesothelioma after Completion of Multimodality Therapy
M. Zauderer (2015)
10.1016/j.jtcvs.2018.10.039
Treatment of malignant pleural mesothelioma with chemotherapy preceding versus after surgical resection
V. Verma (2019)
10.1007/s00508-016-1037-2
Management of malignant pleural mesothelioma – part 3
T. Klikovits (2016)
10.1053/j.ro.2013.03.017
Malignant pleural mesothelioma: role of CT, MRI, and PET/CT in staging evaluation and treatment considerations.
M. Truong (2013)
10.1183/13993003.02189-2016
Intensive care in thoracic oncology
A. Meert (2017)
10.3978/j.issn.2225-319X.2012.11.12
Multimodality therapy for malignant pleural mesothelioma.
W. Weder (2012)
10.3978/j.issn.2072-1439.2013.08.08
Malignant pleural mesothelioma: current and future perspectives.
Konstantinos Porpodis (2013)
10.1093/annonc/mdq173
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
R. Stahel (2010)
10.1007/978-3-030-16884-1_15
Role of Chemotherapy in the Management of Malignant Pleural Mesothelioma
L. Gianoncelli (2019)
10.1016/J.PNEUMO.2011.04.002
Mésothéliome pleural : où en sont la chirurgie radicale et le traitement multimodal ?
Pierre Bonnette (2011)
10.1016/S1470-2045(17)30459-X
Radiotherapy for the treatment of malignant pleural mesothelioma.
M. Perrot (2017)
10.4236/JCT.2014.51008
Malignant Pleural Mesothelioma: Treatment Options and Novel Therapies
J. Martin (2014)
10.1007/s11864-019-0613-x
Use of Immune Checkpoint Inhibitors in Mesothelioma
P. Forde (2019)
10.1007/978-3-319-62642-0_16
Mesothelioma and Thymic Tumors
M. Wahl (2018)
A narrative review of current treatment strategies and emerging therapies in malignant pleural mesothelioma
Élise Di Lena (2020)
Malignant Pleural Mesothelioma and the Role of Non – Operative Therapies Kelvin
C. Ng (2018)
10.1016/j.lungcan.2016.07.023
How does the timing of chemotherapy affect outcome following radical surgery for malignant pleural mesothelioma?
A. Sharkey (2016)
10.1007/s00595-015-1275-3
Current surgical strategies for malignant pleural mesothelioma
T. Takuwa (2015)
10.1016/S1877-1203(13)70385-9
Traitements médicaux du mésothéliome
Sophie M. Jaillard (2013)
10.1093/jjco/hyt035
A feasibility study of induction pemetrexed plus cisplatin followed by pleurectomy/decortication aimed at macroscopic complete resection for malignant pleural mesothelioma.
M. Shimokawa (2013)
10.1093/ejcts/ezw215
Comorbidity, postoperative morbidity and survival in patients undergoing radical surgery for malignant pleural mesothelioma.
Maurizio Infante (2016)
Zahlen und Fakten zum Pleuramesotheliom im 21. Jahrhundert: Epidemiologie, Diagnostik, Therapie // Numbers and facts regarding the malignant pleural mesothelioma in the 21st century: epidemiology, diagnostics, therapy
Watzka Sb (2019)
10.21037/JTD.2019.02.61
Extra-pleural pneumonectomy.
Leonardo Duranti (2019)
10.1016/j.radonc.2017.08.003
The role of radical radiotherapy in the management of malignant pleural mesothelioma: A systematic review.
M. Ashton (2017)
10.1007/978-3-030-16884-1_13
Surgery and Multimodality Treatment in Malignant Pleural Mesothelioma
F. Rea (2019)
10.1080/00015458.2014.11681020
Malignant Pleural Mesothelioma: Rationale for a New TNM Classification
C. D. Laet (2014)
10.1097/JTO.0b013e31826915f1
Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database
V. Rusch (2012)
10.21037/jtd.2018.04.63
The management of malignant pleural mesothelioma in the USA 2004-13-a decade of lost opportunity?
D. Waller (2018)
Mesothelioma and Radical Surgery (MARS): a randomised controlled trial of extrapleural pneumonectomy for malignant pleural mesothelioma
T. Treasure (2011)
10.1016/j.lungcan.2013.11.026
A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma.
C. Cao (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar